Summary
This retrospective cohort study examined whether H. pylori infection status influences treatment outcomes in patients with advanced gastric cancer receiving S-1 adjuvant chemotherapy. The authors report that H. pylori-seropositive patients demonstrated superior overall and disease-free survival compared to seronegative patients, suggesting that H. pylori-induced immune modulation may enhance chemotherapeutic efficacy. The mechanism underlying this association remains unclear and warrants further mechanistic investigation.
UK applicability
Whilst gastric cancer incidence differs between Japan and the United Kingdom, the immunological mechanisms proposed may be relevant to understanding host-pathogen interactions in cancer therapeutics. However, H. pylori prevalence and screening practices differ substantially between populations, limiting direct applicability to UK clinical practice without confirmatory studies in Western cohorts.
Key measures
Overall survival, disease-free survival, H. pylori serostatus (serology), chemotherapeutic response rates
Outcomes reported
The study measured overall survival and disease-free survival in advanced gastric cancer patients stratified by H. pylori serostatus following S-1 based adjuvant chemotherapy. Survival outcomes were compared between H. pylori-positive and H. pylori-negative patient cohorts.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.